Clin Osteol 2013; 18(1): 22-32

Ankylosing spondylitis (Bechterew's disease) from an osteological perspectiveReview articles

S. Skácelová

Ankylosing spondylitis is a chronic rheumatic inflammatory disease mostly affecting the axial skeleton. Initial inflammatory changes in subchondral bone of the sacroiliac, vertebral and apophysealjoints associated with bone tissue erosion are followed by intensive bo­ ne formation processes leading to ankylosis of the affected structures. Patients with ankylosing spondylitis were shown to have abnor­ malities in complex systems participating in bone remodeling regulation (RANKL/RANK/OPG, Wnt/Dkk-1, Wnt/sclerostin and BMP/noggin), mediated by anti-inflammatory cytokines in some cases. The patients have higher prevalence rates of osteoporosis, par­ ticularly of the axial skeleton, and osteoporotic deformities of the vertebral bodies. Severe spinal fractures affecting the vertebral bodies, their processes, syndesmophytes and calcified discs, often complicated by neurological population.

Keywords: osteoporosis, ankylosing spondylitis, spinalfracture

Published: June 11, 2013  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Skácelová S. Ankylosing spondylitis (Bechterew's disease) from an osteological perspective. Osteologický bulletin. 2013;18(1):22-32.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Van der Linden S, Van der Heijde D, Landewé R. Classification and epidemi gy of spondylarthritis. In: Hochberg MC, Silman AJ, Smolen JS, Weinblatt ME, Weisman MH. Rheumatology. Philadelphia, Mosby Elsevier, 2008:1103-1108.
    2. Reveille J. Clinical features of ankylosing spondylitis. In: Hochberg MC, AJ, Smolen JS, Weinblatt ME, Weisman MH. Rheumatology. Philadelphia, Mosby Elsevier, 2008:1109-1114.
    3. Maksymowych WP. Etiology, pathogenesis and athology of ankylosin spondyli­ tis. In: Hochberg MC, Silman AJ, Smolen JS, Weinblatt ME, Weisman MH. Rheumatology. Philadelphia, Mosby Elsevier, 2008:1115-1130.
    4. Resnick D. Ankylosing spondylitis. In: Resnick D, Kransdorf MJ. Bone and imaging. Philadelphia, Elsevier Saunders, 2005:267-287. Go to original source...
    5. Salonen DC, Brower AC. Seronegative spondylartrhopathies: paging. In: Hochberg MC, Silman AJ, Smolen JS, Weinblatt ME, Weisman MH. Rheumatology. Philadelphia, Mosby Elsevier, 2008:1131-1142.
    6. Geusens P, Lems WF. Osteoimmunology and osteoporosis. Arthritis Res Ther 2011;13:242. Go to original source...
    7. Holstead Jones D, Kong YY, Penninger JM. Role of RANKL and RANK in bone loss and arthritis. Ann Rheum Dis 2002;61(SupplII):ii32-ii39). Go to original source...
    8. Sipos W, Pietschmann P, Rauner M. Strategies for novel therapeutic approaches targeting cytokines and signaling pathways of osteoclasto- and osteoblastogene in the fight against immune-mediated bone and joint diseases. Curr Med Chem 2008;15(2):127-136. Go to original source...
    9. Johnson ML, HarnishK, Nusse R, Van Hul W. LRP5 and Wnt signaling: a union made for bone. J Bone Miner Res 2004;19(11):1749-1757. Go to original source...
    10. Diarra D, Stolina M, Polzer K, Zwerina J, Ominsky MS, Dwyer E et al. Dickkopf 1 is a master regulator ofjoint remodeling. Nat Med 2007;13:156-163. Go to original source...
    11. Lories RJ, Derese I, Luyten FP. Modulation of bone morphogenetic protein sig­ naling inhibits the 2005;115:1571-1579.
    12. Carter S, Braem K, Lories JR. The role of bone morphogenetic proteins in an losing spondylitis. Ther Adv Musculoskel Dis 2012;4(4):293-299. Go to original source...
    13. Daoussis D, Liossis SN, Solomou EE, Tsanaktsi A, Bounia K, Karampetsou M et al. Evidence that Dkk-1 is dysfuntional in ankylosing spondylitis. Arthritis Rheum 2010;62:150-158. Go to original source...
    14. Daoussis D, Andonopoulos AP. The emerging role of Dickkopf-1 in bone biolo­ gy: is it the main swi Rheum 2011;41:170-177. Go to original source...
    15. Appel H, Ruiz-Heiland G, Listing J,Zwerina J, Herrmann M, Mueller R, Haibel H, Baraliakos X, Hempfing A, Redwaleit M, Sieper J, Schett G. Altered skeletal expression of sclerostin and its link to radiograph spondylitis. Arthritis Rheum 2009;60(11):3257-3262. Go to original source...
    16. Schett G, Sieper J. In 2009;27(Suppl.55):S33-S35.
    17. Lories RJ, Luyten FR, de Vlam K. Progress in spondylarthritis. Mechanisms of new bone S62-S67.
    18. Vosse D, de Vlam K. Osteoporosi dylitis. 2009;27(Suppl 55):S62-S67.
    19. Baraliakos X, Listing J, Rudwaleit M, Sieper J, Braun J. The relationship betw inflammation and new bone formation in patients with ankylosing spondylitis. Arthritis Res Ther 2008;10(5):R104. Go to original source...
    20. Will R, Palmer R, Bhalla AK, Ring F, Calin A. Osteoporosis in early ankylosing spondylitis: a primary pathological event? Lancet 1989;2:1483-1485. Go to original source...
    21. Lee YS, Schlotzhauer T, Ott SM, van Vollenhoven RF, Hunter J, Shapiro J, Marcus R, McGuire JL. Skeletal status of men with early and late ankylosing spondylitis. Am J Med 1997;103:233-241. Go to original source...
    22. Van der Weijden MAC, Claushuis TAM, Nazari T, Lems FW, Dijkmans BAC, vander Horst-Bruinsma IE. High prevalence of low bone mineral density in pa­ tients within 10 years of on Rheumatol 2012;31:1529-1535. Go to original source...
    23. Gratacós J, Collado A, Filella X, Sanmartí R, Canette J, Llena J et al. Serum tokines (IL-6, TNFa, IL-1p and IFN-y) in ankylosing spondylitis: a close correla­ tion between serum IL-6 and disease activity and severity. Br J Rheumatol 1994;33:927-931. Go to original source...
    24. Visvanathan S, Wagner C, Marini JC, Baker D, Gathany T, Han J, van der Heijde D, Braun J. Inflammatory biomarkers, disease activity and spinal disease mea­ sures in patients with ankylosing spondylitis after treatment with infliximab. Ann Rheum Dis 2008;67:511-517. Go to original source...
    25. Brandt J, Haibel H, Cornely D, Golder W, Gonzalez J, Reddig J, Thriene W, Sieper J, Braun J. Successful tratment of active ankylosing spondylitis with the anti-tumor necrosis factor alpha monoclonal antibody infliximab. Arthritis Rheum 43:1346-1352. Go to original source...
    26. Allali F, Breban M, Porcher R, Maillefert JF, Dougados M, Roux C. Increse in ne mineral density of patients with spondylarthropathy treated with anti-tumour necrosis factor. Ann Rheum Dis 2003;62:347-349. Go to original source...
    27. Marzo-Ortega H, McGonagle D, Haugeberg G, Green MJ, Stewart SP, Emery P. Bone mineral density improvement in spondylarthropathy after treatment with etanercept. Ann Rheum Dis 2003;62:1020-1021. Go to original source...
    28. Visvanathan S, van der Heijde D, Deodhar Atul, Wagner C, Baker DG, Han John, Braun J. Effects of infliximab on markers of inflammation and bone turnover and associations with bone mineral density in patients with ankylosing spondylitis. Ann Rheum Dis 2009;68(2):175-182. Go to original source...
    29. Barnabe Ch, Hanley DA Effect of tumor necrosis factor alpha inhibition on density and turnover markers in patients with rheumatoid arthritis and spondy­ larthropathy. Semin Arthritis Rheum 2008;39:116-122. Go to original source...
    30. Confavreux CB, Chapurlat RD. Systemic bone effects ofbiologic therapies in umatoid arthritis and ankylosing spondylitis. Osteoporos In 2011;22:1023-1036. Go to original source...
    31. Korkosz M, Gasowski J, Grzanka P, Gorczowski J, Pluskiewicz W, Jeka S, Grodzicki T. Baseline new bone formation does not predict bone loss in ankylo­ sing spondlyitis as asessed by quantitative computed tomography (qCT)-10-year follow-up. BMC Musculoskeletal Disorders 2011;12:121. Go to original source...
    32. Karberg K, Zochling J, Sieper J, Felsenberg D, Braun J. Bone loss is detecte re frequently in patients with ankylosing spondylitis with syndesmophytes. J Rheumatol 2005;32:1290-1298.
    33. Lange U, Kluge A, Strunk J, Teichmann J, Bachmann G. Ankylosing spondylitis and bone mineral density - what is the ideal tool for measurement? Rheumatol Int 2005;26:115-120. Go to original source...
    34. Roux C. Osteoporosis in inflammatory joint diseases. Osteoporos Int 2011;22: 421433. Go to original source...
    35. Ghozlani I, Ghazi M, Nouijai A, Mounach A, Rezqi A, Achemlal L, Bezza A, El Maghraoui A Prevalence and risk factors of osteoporosis and vertebral fractures in patients with ankylosing spondylitis. Bone 2009;44:772-776. Go to original source...
    36. Kaya A, Ozgocmen S, Kamanli A, Ardicoglu O. Bone loss in ankylosing spondy­ litis: does syndesmophyte formation have an influence on bone density changes? Med Princ Pract 2009;18:470^76. Go to original source...
    37. Weiss JR, Wick MC, Ackermann PV, Montgomery SM. Increased fracture risk in patients with rheumatic disorders and other inflammatory diseases-a case control study with 53,108 patients with fracture. J Rheumatol 2010;37:2247-2250. Go to original source...
    38. Vosse D, Landewé R, vand der Heijde D, van der Linden S, van Staa TP. Ankylosing spondylitis and the risk of fracture: results from a large primary ca based nested case control study. Ann Rheum Dis 2009;68:1839-1842. Go to original source...
    39. Cooper C, Carbone L, Michet CJ, Atkinson EJ, O'Fallon WM, Melton LJ. Fracture risk in patients with ankylosing spondylitis: a population based study. J Rheumatol 1994;21:1877-1882.
    40. MitraD, Elvins DM,Speden DJ, Collins AJ. The prevalence of vertebral fract in mild ankylosing spondylitis and their relationship to bone mineral density. Rheumatol 2000;39:85-89. Go to original source...
    41. Ralston SH, Urquhart GD, Brzeski M, Sturrock RD. Prevalence of vertebral com­ pression 563-565.
    42. Montala N, Juanola X, Collantes E, Munoz-Gomariz E, Gonzalez C, Gratacos J et al. Prevalence of vertebral fractures by semiautomated with ankylosing spondylitis. J Rheumatol 2011;38:893-897. Go to original source...
    43. Klingberg E, Geijer M, Gothlin J, Mellstrom D, Lorentzon M, Hilem E, Hedber M, Carlsten H, Forsblad-D'Elia H. Vertebral fractures in ankylosing spondylitis are associated with lower bone mineral density in both central and periphe leton. J Rheumatol 2012;39:1987-1995. Go to original source...
    44. Van der Weijden MAC, van der Horst-Bruinsma, van Denderen JC, Dijkmans BAC, Heymans MKW, Lems WF. High frequency of vertebral fractures in early spondylarthropathies. Osteoporos Int 2012;23:1683-1690. Go to original source...
    45. Caron T, Bransford R, Nguyen Q, Agel J, Chapman J, Bellabarba C. Spine frac­ tures in patients with ankylosing spinal disorders. Spine 2010;35(11):E458-E464. Go to original source...
    46. Westerveld LA, Verlaan JJ, Oner FC. Spinal fractures in patients with ankylosing spinal disorders: a systematic review of the literatu status and complications. Eur Spin J 2009;18:145-156. Go to original source...
    47. Alaranta H, Luoto S, Konttinen YT. Traumatic spinal cord injury as a compli tion to ankylosing spondylitis. An extended report. Clin Exp Rheumatol 2002;20: 66-68.
    48. Jacobs WB, Fehlings MG. Ankylosing spondylitis and spinal cord i incidence, management and avoidance. Neurosurg Focus 2008;24(1):E12. Go to original source...
    49. Chaudhary SB, Hullinger H, Vives MJ. Management of acute spinal fractures ankylosing spondylitis. Rheumatol 2011;150484. Epub 2011 Jun 30. Go to original source...
    50. Anwar F, Al-Khayer A Joseph G, Fraser MH, Jigajinni MV, Allan DB. Delayed presentation and diagnosis of cervical spin spondylitis. Eur Spine J 2011;20(3):403^07. Go to original source...
    51. Heyde CE, Fakler JK, Hasenboehler E, Stahel PF, John T, Robinson Y, Tschoeke SK, Kayser R. Pitfalls and complications in the treatment of cervical spine fr res in patients with ankylosing spondylitis. Patient Saf Surg 2008;2:15. Go to original source...
    52. Kang KY, Lee KY, Kwok SI, Ju JH, PKS, HYS, Kim HY, Park SH. The change of bone mineral density according to treatment agents in patients with ankylosing spondylitis. Joint Bone Spine 2011;78:188-193. Go to original source...

    Return to the content


    Clinical Osteology

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.